KDR and neoplasm: To further improve the DR5-B antitumor efficacy by engaging additional tumor targets, we have recently engineered a multitarget fusion protein SRH-DR5-B-iRGD, containing VEGFR2-specific peptide SRH at the N-end and integrin αvβ3/NRP1-specific peptide iRGD at the C-end of the DR5-B protein.